Abstract
Accumulating evidence suggests that oxidative stress and inflammation play a role in the pathophysiology of psychiatric disorders such as schizophrenia and depression. Blood levels of pro-inflammatory cytokines in patients with schizophrenia or depression were significantly higher than those of healthy controls. Together, antioxidants and anti-inflammatory compounds have been suggested as the novel therapeutic drugs for schizophrenia and depression. Here the author would like to discuss the possibility of sulforaphane as prophylactic compound for schizophrenia and depression.
